Abstract

Biparametric MRI (bpMRI), which uses only T2-weighted imaging and diffusion-weighted imaging, continues to gain support for the detection of prostate cancer, as this imaging technique offers many benefits over traditional mpMRI. However, the Prostate Imaging Reporting and Data System (PI-RADS) v2.1 document released in 2019 emphasized that mpMRI is still preferred over bpMRI in most clinical scenarios. As one article in a series of four providing arguments for and against using mpMRI and bpMRI protocols, this paper provides arguments against using mpMRI. Within this article, we discuss recent data suggesting equivalent performance between bpMRI and mpMRI in the detection of prostate cancer. The limited utility of dynamic contrast enhancement in the evaluation of prostate cancer according to the PI-RADS v2.1 document is also reviewed. Finally, we detail the large financial and time costs, legal and logistical issues, and potential for patient harm that must be considered with the administration of contrast.

中文翻译：

---

圆桌会议：反对使用多参数前列腺MRI方案的论点

摘要

仅使用T2加权成像和扩散加权成像的双参数MRI（bpMRI）继续获得对前列腺癌检测的支持，因为这种成像技术比传统的mpMRI更具优势。但是，2019年发布的前列腺成像报告和数据系统（PI-RADS）v2.1文档强调，在大多数临床情况下，mpMRI仍然比bpMRI更为可取。作为一系列四篇文章中的一篇，它提供了反对使用mpMRI和bpMRI协议的论据，本文提供了反对使用mpMRI的论据。在本文中，我们讨论了最近的数据，这些数据表明bpMRI和mpMRI在检测前列腺癌方面具有同等的性能。还回顾了根据PI-RADS v2.1文档在评估前列腺癌中动态对比增强的有限效用。最后，